BNET Industries

Synta Pharmaceuticals Corp.

(SNTA) is in the Pharma Industry

Market Cap:$186.5M
Last Fiscal Year Sales:$2.6M
  • Public
  • US
Dow Jones Description

We are a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We have three clinical-stage drug candidates and several drug candidates in the preclinical and discovery stages, each of which has a distinct chemical structure, mechanism of action, and market opportunity. Each of our drug candidates was discovered and developed internally using our proprietary, unique chemical compound library and integrated discovery engine. In October 2007, as amended in June 2008, we entered into a global collaborative development, commercialization and license agreement, or the GSK Agreement, with GlaxoSmithKline, or GSK, for the joint development and commercialization of elesclomol, one of our oncology drug candidates. In December 2008, we entered into a collaborative license agreement, or the Roche Agreement, with Hoffmann-La Roche, or Roche, for our CRACM inhibitor program, which is currently in the lead optimization stage. We retain all rights to our other drug candidates and programs. We believe that our demonstrated ability to generate new drug candidates from our discovery platform, our ability to effectively enroll and conduct clinical trials, and our ability to enter into partnerships with leading multinational pharmaceutical companies are important competitive advantages. ...

Number of Employees 129
Contact Information

45 Hartwell Ave

Lexington, Massachusetts 02421-3102

syntapharma.com

(781) 274-8200

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Synta Pharma SNTA Releases Data Relating to Elesclomol Against AML Cell Lines

    12/07/09 - Product Announcement - View Story

  • Roth Capital Upgrades Synta Pharmaceuticals SNTA to Buy

    11/05/09 - Bond / Stock Rating - View Story

  • Synta Pharmaceuticals posts net income in Q3

    11/06/09 - Financial Announcement - View Story

  • Synta Pharmaceuticals Reports Second Quarter 2009 Financial Results

    8/04/09 - Financial Announcement - View Story

  • Synta Pharmaceuticals SNTA Names Dr. Vojo Vukovic as Chief Medical Officer

    6/19/09 - Mgmt. Change Entering - Vice President - View Story

News & Analysis

biotechnology and synta pharmaceuticals corp. - All News and Analysis

advertisement
     SNTA $5.49 +0.07 (1.29% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 66,630
Shares Outstanding 33.98M
Market Cap 186.5M
Year High 9.55
Year Low 1.2
Earnings Per Share 1.77
P/E Ratio 3.10
Dividend N/A
Yield N/A
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here
Presented by American Express